Tumor metastasis in an orthotopic murine model of head and neck cancer: Possible role of TGF-beta 1 secreted by the tumor cells

Journal of Cellular Biochemistry

Volumn 97, Issue 5, 2006, Pages 1036-1051

  Dasgupta, Santanu ^a   Bhattacharya Chatterjee, Malaya ^a   O'Malley Jr , Bert W ^b   Chatterjee, Sunil K ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Head and neck cancer; Metastasis; TGF beta 1

Indexed keywords

CD31 ANTIGEN; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ARTICLE; CELL SECRETION; FEMALE; GROWTH INHIBITION; HEAD AND NECK CANCER; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; MOUSE; NONHUMAN; ORTHOPTICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; VIRUS EXPRESSION;

ANIMALS; ANTIGENS, CD31; CADHERINS; CELL LINE, TUMOR; FEMALE; LYMPH NODES; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C3H; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASES; TONGUE NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VACCINATION; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VIRAL VACCINES;

ANIMALIA; MURINAE; VACCINIA VIRUS;

EID: 33645220048     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20647     Document Type: Article

References (28)

1. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. 2001. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574.
2. Chambers AF, Matrisian LM. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270.
3. Curran S, Murray GI. 1999. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189:300-308.
4. Dasgupta S, Tripathi PK, Bhattacharya-Chatterjee M, O'Malley B, Jr., Chatterjee SK. 2003. Recombinant vaccinia virus expressing IL-2 generates effective anti-tumor responses in an orthotopic murine model of head and neck carcinoma. Mol Ther 8:238-248.
5. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW, Jr., Chatterjee SK. 2004. Reversal of immune suppression following vaccination with recombinant vaccinia virus expressing IL-2 in an orthotopic murine model of head and neck squamous cell carcinoma. Cancer Ther 2: 375-388.
6. De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, Badellino F, Cortesina G. 2002. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer 95:90-97.
7. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. 2002. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94:2766-2792.
8. Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH. 1997. Latent transforming growth factor beta1 activation in situ: Quantitative and functional evidence after low-dose gamma-irradiation. FASEB J 11:991-1002.
9. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. 2002. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95: 1902-1910.
10. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. 2004. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64:55-63.
11. Hofmann UB, Eggert AA, Blass K, Brocker EB, Becker JC. 2003. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 63:8221-8225.
12. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. 2001. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197.
13. Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJ, Hokland ME, Goldfarb RH. 2000. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J Immunol 164:5883-5889.
14. Kim ES, Kies M, Herbst RS. 2002. Novel therapeutics for head and neck cancer. Curr Opin Oncol 14:334-342.
15. Li D, Jiang W, Bishop JS, Ralston R, O'Malley BW, Jr. 1999. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res 5:1551-1556.
16. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. 2004a. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 84:8-20.
17. Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, Wang XJ. 2004b. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 64:4405-4410.
18. McCawley LJ, Matrisian LM. 2001. Tumor progression: Denning the soil round the tumor seed. Curr Biol 11: R25-R27.
19. Nagase H. 1997. Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151-160.
20. O'Malley BW, Jr., Cope KA, Johnson CS, Schwartz MR. 1997. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 123:20-24.
21. Qin H, Chatterjee SK. 1996. Recombinant vaccinia expressing interleukin-2 for cancer gene therapy. Cancer Gene Ther 3:163-167.
22. Qin H, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, O'Malley BW, Jr., Chatterjee SK. 2001. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol Ther 4:551-558.
23. Rodrigo JP, Dominguez F, Alvarez C, Manrique C, Herrero A, Suarez C. 2002. Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer 38: 1059-1064.
24. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. 1999. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 5: 775-782.
25. Trudel D, Fradet Y, Meyer F, Harel F, Tetu B. 2003. Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res 63:8511-8515.
26. Weeks BH, He W, Olson KL, Wang XJ. 2001. Inducible expression of transforming growth factor beta1 in papillomas causes rapid metastasis. Cancer Res 61: 7435-7443.
27. Werner JA, Rathcke IO, Mandic R. 2002. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 19:275-282.
28. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM. 2002. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109:1607-1615.